HT3 A FRAMEWORK FOR DERIVING A MINIMALLY ACCEPTABLE TARGET CLINICAL PROFILE AND A MAXIMUM VALUE-BASED PRICE FOR DRUGS IN DEVELOPMENT TO MEET HEALTH TECHNOLOGY ASSESSMENT REQUIREMENTS
May 1, 2009, 00:00 AM
10.1016/S1098-3015(10)73117-X
https://www.valueinhealthjournal.com/article/S1098-3015(10)73117-X/fulltext
Section Title :
Section Order :
63
First Page :
https://www.valueinhealthjournal.com/action/showCitFormats?pii=S1098-3015(10)73117-X&doi=10.1016/S1098-3015(10)73117-X